Key Highlights
- Enhanced early phase development with the acquisition of cutting-edge pharmaceutical technologies.
- Investment in the 3P Innovations API in capsule filling machine, FT4 Powder Rheometer®, and STYL’One Nano compaction simulator.
- Faster timelines, improved stability, and reduced risk in drug candidate development and manufacturing.
Source: Business Wire
Notable Quotes
- “The introduction of these technologies underscores our commitment to innovation and our clients’ success,” – Justin Keen, Senior Vice President, Operations at AustinPx
- “This investment demonstrates our continued commitment to our clients’ needs and our goal of always looking for ways to move our clients’ drug candidates into the clinic more efficiently without compromising quality,” – Elizabeth Hickman, Chief Business Officer at AustinPx
SoHC's Take
AustinPx’s recent strategic acquisitions mark a significant enhancement in their service offerings to the pharmaceutical industry. By integrating the 3P Innovations API in capsule filling machine, FT4 Powder Rheometer®, and the STYL’One Nano compaction simulator into their arsenal, AustinPx not only accelerates the drug development process but also ensures higher stability and reduced risks. This move is a testament to AustinPx’s relentless pursuit of excellence and innovation in the pharmaceutical development sector. Through such investments, AustinPx is well-positioned to meet the evolving needs of their clients, reinforcing their status as a leading contract development and manufacturing organization (CDMO). The commitment to reducing development timelines without sacrificing quality reflects a deep understanding of the current challenges in the pharmaceutical industry and underscores AustinPx’s role as a key player in advancing drug development efficiencies.
